Votrient

Votrient is a brand name of pazopanib, approved by the FDA in the following formulation(s):

VOTRIENT (pazopanib hydrochloride - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: October 19, 2009
  
  Strength(s): EQ 200MG BASE, EQ 400MG BASE ^[RLD]

Has a generic version of Votrient been approved?

No. There is currently no therapeutically equivalent version of Votrient available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Votrient. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pyrimidineamines as angiogenesis modulators
  Patent 7,105,530
  Issued: September 12, 2006
  Inventor(s): Boloor; Amogh & Cheung; Mui & Davis; Ronda & Harris; Philip Anthony & Hinkle; Kevin & Mook, Jr.; Robert Anthony & Stafford; Jeffery Alan & Veal; James Marvin
  Assignee(s): SmithKline Beecham Corporation
  Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also Includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
  
  Patent expiration dates:
  
  
  • December 19, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pyrimidineamines as angiogenesis modulators
  Patent 7,262,203
  Issued: August 28, 2007
  Inventor(s): Boloor; Amogh & Cheung; Mui & Davis; Ronda & Harris; Philip Anthony & Hinkle; Kevin & Mook, Jr.; Robert Anthony & Stafford; Jeffery Alan & Veal; James Marvin
  Assignee(s): SmithKline Beecham Corporation
  Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
  
  Patent expiration dates:
  
  
  • December 19, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 19, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Votrient Consumer Information (Drugs.com)
• Votrient Consumer Information (Wolters Kluwer)
• Votrient Consumer Information (Cerner Multum)
• Votrient Advanced Consumer Information (Micromedex)
• Votrient AHFS DI Monographs (ASHP)
• Pazopanib Consumer Information (Wolters Kluwer)
• Pazopanib Consumer Information (Cerner Multum)
• Pazopanib Advanced Consumer Information (Micromedex)
• Pazopanib Hydrochloride AHFS DI Monographs (ASHP)